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 Bronchial asthma (BA) - a chronic inflammatory 
disease of the airways involving eosinophils, 
lymphocytes (T helper cells), macrophages, 
basophils, mast cells, neutrophils, which is 
characterized by generalized bronchial 
obstruction of different severity, which may be 
partially or fully reversible (spontaneously or 
under bronchodilator effect), and the 
phenomenon of bronchial hyperreactivity. 
(Global strategy for the prevention and 
treatment of asthma, GINA). 
 This initiative was created with the aim of raising 
awareness of BA among medical professionals, 
health authorities and society in general to 
improve the prevention and treatment of BA by 
coordinating efforts around the world. GINA 
prepares scientific reports with BA, promotes the 
dissemination and implementation of 
recommendations, and also supports 
international cooperation in the field of BA 
research. The GINA 2016 preview and other GINA 
publications can be found at 
www.ginasthma.com
 Chronic inflammation can be induced through contact 
with an allergen, pollutants, industrial factor, and 
acute viral infection. The inflammatory process leads 
to four forms of bronchial obstruction, acute spasm 
of smooth muscles of the respiratory tract, subacute
swelling of the mucous membrane of the respiratory 
tract, chronic formation of viscous bronchial 
secretions and irreversible sclerotic process in the 
airways. BA may be of non-allergic origin, such as a 
brain injury, resulting in endocrine disorders. 
Infectious-allergic asthma develops against various 
infectious respiratory disease (pneumonia, bronchitis, 
tonsillitis, nasopharyngitis), where bacteria are 
antigens. In most cases, they are opportunistic and 
saprophytic flora (S. aureus, E. coli, Klebsiella spp.).
Inducers of asthma most often are: 
 - Household allergens
 - Allergens of animal origin: wool, feathers, droppings, 
saliva of animals and insects, Daphnia and other; 
 - Fungal allergens, mold and yeast fungi (Alternaria, 
Aspergillus, Mucor, Candida, Penicillum, Cladosporium); 
 - Pollens allergens three main plants: trees, shrubs, 
grasses and weeds; 
 - Food allergens; 
 - Drugs: antibiotics, particularly penicillin, vitamins, 
aspirin and other nonsteroidal antiinflammatory drugs; 
 - Viruses and vaccines
 The inflammation of the bronchial mucosa occurs at the early 
stages of asthma. Activation of T-helper cells leads to the 
production of cytokines that characterize as "allergic" 
inflammation. There is also a migration of eosinophils into 
the bronchial tree, their activation with subsequent release of 
vasoactive substances that damage the bronchial mucosa 
tissue. Neutrophil’s inflammatory nature predominates in 
acute severe asthma attacks associated with sudden death. In 
severe forms of asthma there is increase in the number of 
macrophages. Mast cells play an important role in the 
immediate response to allergen exposure due to the 
production of proinflammatory cytokines. The consequence 
of chronic inflammation in asthma is remodeling of lung 
tissue, destruction of epithelial cells by desquamation 
thickening basement membrane disruption basic substance, 
hyperplasia and hypertrophy of smooth muscles of the 
bronchi. There is a relationship between the concentration of 
serum immunoglobulin E (IgE), the clinical signs of bronchial 
asthma and hyperactivity.
 In the pathogenesis of asthma are three 
stages: 1) immune - under various allergens 
produce antibodies or lymphocytes 
sensitization occurs; 2) patochemical - with 
repeated action of allergens out of mast cells 
mediators; 3) pathophysiological -
development of bronchial obstruction 
syndrome.

 According to this classification, the patient's 
condition is determined by the severity of 
asthma. Intermittent (episodic) course, 
persistent (permanent) course are: easy, 
moderate and hard.
Clinical symptoms before treatment: 
Symptoms (episodes of coughing, wheezing, 
shortness of breath) short-term, there are at 
least 1 time per week for at least 3 months 
 Short-term aggravation 
 Night symptoms occur no more than 2 times a 
month 
 The absence of symptoms, normal values of 
between exacerbations.FEV1(Forced Expiratory 
Volume in one second) or Volume of exhale> 
80% of the relevant 
 Daily fluctuations Volume of exhale or 
FEV1<20%.
Clinical symptoms before treatment: 
 • Symptoms often, at least - once day a week, 
but less than 1 time per day for more than 3 
months 
 • Exacerbation of symptoms can disrupt sleep 
and activity; 
 • The presence of chronic symptoms that require 
symptomatic treatment almost daily; 
 • Night asthma symptoms occurring more than 2 
times a month; 
 • FEV1 or Volume of exhale> 80% of the relevant
 • Daily fluctuations Volume of exhale or FEV1 -
20-30%.
Clinical symptoms before treatment: 
 • Symptoms occur daily 
 • Worsening lead to disruption of activity and 
sleep 
 • Night asthma symptoms occur more than 1 
time per week 
 • The need for daily intake β2-agonists short 
action 
 • FEV1 or Volume of exhalewithin 60-80% of the 
relevant 
 • Daily fluctuations Volume of exhaleor FEV1> 
30%.
Clinical symptoms before treatment: 
 There is presence of largely variable long 
symptoms, frequent nocturnal symptoms, activity 
limitation, and severe exacerbation. Despite the 
treatment, which is carried out, the absence of 
proper control of the disease 
 • The constant presence of long daytime 
symptoms; 
 • Frequent night symptoms; 
 • Frequent, severe exacerbation; 
 • Limit physical activity caused by asthma; 
 • FEV1 or Volume of exhale30%;
Symptoms of asthma: 
 - Episodic breathlessness with difficulty in 
exhaling; 
 - Cough more at night and during exercise; 
 - Occasional whistling wheezing in the lungs;
 - Stiffness of the chest. 
 Symptoms are mostly aggravated at night and 
in the early morning hours, and awaken the 
patient
 During the attack patients often take a forced 
sitting or standing position with incline of 
body forward, leaning on hand with a raised 
shoulder and summary
 Severe emotional reaction - the patient 
concerned, suffering facial expression, 
scared, can barely speak. 
 The face of the patient during an attack puffy, 
covered with cold sweat, wings swellsof nose 
during inhalation, neck veins dilated
 Spirometry is one type of pulmonary function test. 
Spirometry is a simple test to measure how much 
(volume) and how fast (flow) you can move air into 
and out of  your lungs.
 1. Hemogramm (Eosinophilia, lymphocytosis, and a 
tendency to leukopenia. Prolonged severe course may 
develop compensatory increase of erythrocyte and 
hemoglobin). 
 2. Analysis of sputum (eosinophilia bronchial secretions, 
Curschmann’s spirals, Charcot-Leyden crystals). 
 3. X-ray study (as determined by increased transparency 
of the lung fields, strengthening of pulmonary picture, the 
expansion of the roots of the lungs. The typical low 
standing, low mobility dome of diaphragm. The ribs are 
horizontally extended intercostal spaces). 
 4. Electrocardiography (increase in T wave in all leads, 
often increasing the P wave in leads II and III. In severe 
hypoxia infarction observed depression ST segment in I, 
aVL, V 4-6 leads. 
 5.Alergic study (Allergic history - the presence of allergic 
rhinitis patients, atonic dermatitis or asthma or atonic
disease in his family, Leather positive tests with allergens, 
elevated levels of total and specific IgE). 
 Drug therapy for asthma patients spend using 
different routes of administration of drugs -
inhaled, oral and parenteral. The greatest 
advantage is inhalation, providing a strong 
local effect of drugs in the lungs without 
causing their unwanted systemic effects, 
makes it possible to accelerate the positive 
effect of treatment due to lower doses of 
medication. 
 Used daily basis, the long-term basis, to 
achieve and maintain control of persistent 
asthma. Include inhaled corticosteroids, 
systemic corticosteroids, cromones, 
leukotrienes modifiers, longacting
bronchodilators (inhaled β2-agonists, long-
acting oral β2-agonists, long-acting, 
longacting theophylline, long-acting 
anticholinergs) and systemic Steroid-Sparing 
therapy
 Medications are usually given as a metered dose 
inhalation: 
 - spacers 
 - pocket powder inhalers (spinhaler, turbohaler, 
rotohaler) 
 - ultrasonic inhalers 
 - compressor nebulizer inhalers 
 Nebulizers and spacers are equally effective in 
those with mild to moderate symptoms.
 A 44 year old woman, currently working in a bakery, presents 
with a 1 year history of asthma and allergic rhinitis 
symptoms, including episodic cough, wheeze, shortness of 
breath and chest tightness with itchy red watery eyes and a 
stuffy, runny, itchy nose. These symptoms become worse 
within 1-2 hours of starting work each day, and worsen 
throughout the work week. She especially finds red bran to 
worsen her symptoms almost immediately on exposure. She 
notices an improvement within 1-2 hours outside of being at 
her workplace. She has been working in the bakery for 13 
years, and for the last 10 years has been a "pre-scaler", 
weighing components, while wearing a paper mask. The line 
that she has worked on for the last 2 years is dustier than 
other areas.
 Her past medical history is significant for seasonal allergic 
rhinitis in the summer months since childhood. She is a 
lifelong non-smoker. Her family history is significant for 
asthma in her mother and brother. She currently uses an 
inhaled steroid-long acting bronchodilator (ICS-LABA) daily, 
and inhaled short-acting bronchodilator (SABA) as needed, 
generally up to 4 times a day at work with relief.
Physical Exam
 Her physical examination is normal.
Lab
 Her chest x-ray is also normal. Spirometry testing shows 
FEV1/FVC 0.62 (within 24 hours of work), FEV1 1.9L (60% 
predicted), and post-bronchodilator, the FEV1 increases to 
2.2L (300cc, 16%). One year earlier, after 2 months off work, 
her FEV1 was 2.3L. Skin prick testing was positive to grass 
(3+), a slurry of workplace flour (3+), wheat germ (3+), and 
red bran (2+). Her home peak expiratory flow readings ranged 
between 270 and 340, with lower readings on workdays
Diagnosis and Management
 A diagnosis of occupational asthma from wheat 
(including wheat germ and bran) was made. She was 
transferred to a muffin packing area where flour 
exposure was minimal, if any, and was followed with 
further peak flow monitoring and spirometry: she has 
since remained well with no symptoms and requiring 
no medications.
 Spirometry testing shows FEV1/FVC 0.62 (within 24 
hours of work), FEV1 1.9L (60% predicted), and post-
bronchodilator, the FEV1 increases to 2.2L (300cc, 
16%). One year earlier, after 2 months off work, her 
FEV1 was 2.3L. Skin prick testing was positive to 
grass (3+), a slurry of workplace flour (3+), wheat 
germ (3+), and red bran (2+). Her home peak 
expiratory flow readings ranged between 270 and 
340, with lower readings on workdays
In patients with a history of possible 
occupational asthma, which of the following 
is important to establish a diagnosis?
 A. Confirm a diagnosis of asthma objectively
 B. Skin-prick testing where feasible
 C. Induced sputum if available
 D. Peak expiratory flows during and off work
 E. Methacholine challenge at the end of a 
work week and after a period off work
 F. All of the above
 A 55-year-old Japanese female was admitted 
with infected traumatic cutaneous ulcers. The 
infectious organism was Staphylococcus 
aureus, and levofloxacin was administered. She 
had been diagnosed with bronchial asthma 
during childhood and had been treated by her 
family doctor. For several years, her bronchial 
asthma worsened and she was treated with 
fluticasone/salmeterol (500 mcg/100 mcg per 
day), prednisolone (10 mg per day), 
theophylline (400 mg per day), and pranlukast
(leukotriene receptor antagonist, 450 mg per 
day). She had suffered from dyspnea upon 
exertion and wheezing continuously for the 
prior two months. Pulmonary function tests, 
which had been conducted three months before 
admission, showed a pattern of obstruction
 Her bronchial asthma showed exacerbation after admission. 
Laboratory studies revealed a serum lactate dehydrogenase
(LDH) level of 287 international units (IU) per liter, 
myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-
ANCA) levels less than 1.3 IU per milliliter, and an 
immunoglobulin E (IgE) level of 635 IU per milliliter; no 
peripheral blood eosinophils were detected. Her prednisolone
dose was increased to 20 mg per day, but she developed 
dyspnea, wheezing, and hypoxia necessitating inhalation of 
oxygen. This exacerbation of her bronchial asthma persisted for 
a month, despite the increase in prednisolone. Next, 300 mg per 
day of omalizumab was administered; however, her dyspnea
persisted  and her chest radiograph showed atelectasis of the 
left lung. Her CRP level was 0.27 mg per liter. Bronchoscopy
revealed that the left main bronchus and other left bronchi were 
obstructed with colorless viscous sputum. Due to the large 
volume of viscous sputum in the peripheral bronchi, bronchial 
toileting did not improve the atelectasis. No eosinophils or 
malignant cells were identified in suction specimens of the 
sputum, which contained 82% neutrophils and 18% lymphocytes, 
and no bacteria or fungi were detected by sputum cultures. The 
prednisolone dose was increased to 120 mg per day for three 
days and then to 60 mg per day for the remainder of the 
hospitalization
 Panipenem/betamipron (carbapenem
antibiotic) was administered 
concurrently with the prednisolone
treatment for two weeks. However, the 
patient continued to demonstrate severe 
dyspnea, wheezing, and hypoxia that 
required the inhalation of a large 
amount of oxygen, and her atelectasis
did not improve. One month later, she 
was treated with 2 mg per day of 
tacrolimus. Her symptoms and 
respiratory status did not change during 
the first week, but, thereafter, the 
atelectasis improved. Thereafter, her 
dyspnea and hypoxia started to 
gradually improve. After three months 
of tacrolimus administration, oxygen 
administration was stopped and the 
patient became capable of short walks. 
The prednisolone was tapered over the 
course of four weeks to 20 mg per day, 
and she was transferred to another 
hospital for rehabilitation.
A chest radiograph showed 
atelectasis of the left lung.
A chest radiograph showed 
an improvement in the 
atelectasis of the left lung.
 In the current patient, we suspected that the 
cause of atelectasis was exacerbation of 
bronchial asthma. This case was not considered 
to have allergic bronchopulmonary aspergillosis
based on negative findings for IgE specific to 
aspergillus, negative suction sputum cultures, no 
peripheral blood eosinophils, and no central 
bronchiectasis. We also ruled out the possibility 
of allergic bronchopulmonary candidiasis, 
because the only positive finding was IgE specific 
to candida. In addition, there were no signs of 
bacterial infection in her lungs, as demonstrated 
by negative serum CRP, negative suction sputum 
specimen cultures, and a lack of response to 
antibiotic treatment.
 The basic pathology of bronchial asthma is 
chronic airway inflammation with infiltration of 
inflammatory cells such as eosinophils. 
Asthmatics with severe disease have 
predominantly neutrophilic inflammation, in 
contrast to asthmatics whose disease is 
controlled. The significance of neutrophilic
inflammation is not apparent, but when such 
inflammation is not controlled by corticosteroid 
therapy, there is an association with increased 
severity in a subset of severe asthma cases. The 
current patient’s suction sputum specimens, 
which were obtained during bronchoscopy, 
included many neutrophils but no eosinophils. 
Therefore, the patient demonstrated severe 
asthma due to neutrophilic inflammation.
 Tacrolimus is an immunosuppressive agent. This 
drug has a mode of action which is similar to that 
of cyclosporine, namely due to its ability to 
inhibit calcineurin in T cells. Some previous 
studies on humans regarding steroid-dependent 
asthma treated with oral cyclosporine have been 
reported. These results, therefore, suggest that 
cyclosporin might be beneficial in some patients 
with steroid-dependent asthma, while not being 
of any benefit in other patients. Tacrolimus
suppresses the activation of T cells and the 
production of interleukin (IL)-2, IL-3, IL-4, IL-5, 
IL-6, granulocyte/macrophage colony-
stimulating factor (GM-CSF) , interferon-gamma, 
and other proteins. 
 Presented a case of severe bronchial asthma, 
associated with airway inflammation 
characterized by neutrophil infiltration, 
controlled with tacrolimus. Therefore, this 
drug should be considered for the treatment 
of severe asthma, including cases 
demonstrating corticosteroid resistance.
The immunological mechanisms of asthma 
include all of these, except one:
 A. Activation basophilic leukocytes
 B. Hypereosinophilia
 C. activation synthesis reagin
 D. Glucocorticoid deficiency
 E. Hypersensitivity reaction negative type
